BDTX

Black Diamond Therapeutics, Inc.
CAPPED RATING

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Black Diamond Therapeutics, Inc. (BDTX) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D).

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D
Factor Score 1.2 / 5.0
Profitability
D
Factor Score 1.3 / 5.0
Momentum
D+
Factor Score 1.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.5
EV / EBITDA -0.0
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -25.7%
Price Return 12M -65.9%
Catalyst Signal 0.00
Market Cap $87.9M
TTM Revenue $0.0
Price / Sales N/A
ROE -41.1%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) D (1.2) D (1.3) D+ (1.8) C+ (2.6) C- (1.9)
2026-11-10 C+ (2.5) F (0.1) D (1.3) C- (2.0) C+ (2.6) D+ (1.7)
2026-11-03 C+ (2.5) F (0.2) D (1.3) C (2.3) C+ (2.7) D+ (1.8)
2026-10-27 C+ (2.5) F (0.2) D (1.4) C- (2.0) C+ (2.6) D+ (1.7)
2026-10-20 C+ (2.5) F (0.2) D (1.4) C- (2.0) C+ (2.6) D+ (1.7)
Page 1 of 4